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Abstract
Background
Published data showed that the susceptibility of autoimmune diseases (ADs) was associat-
ed with the polymorphism rs2910164 in microRNA-146a (miR-146a). However, the results
remain controversial so far. Two meta-analyses published in 2013 and 2014 came to oppo-
site conclusions. In order to derive a more precise estimation of the relationship, we per-
formed this meta-analysis.
Methods
We searched the PubMed, OvidSP and CNKI databases (published prior to September 8th,
2014) and extracted data from eligible studies. The procedure of meta-analysis was per-
formed by using the Stata 12.0 software. Random effect model or fixed effect model were
chosen respectively, according to the between study heterogeneities.
Results
A total of 24 case-control studies, 11 more than previous meta-analysis on this topic, were
involved. We took stratified analyses by different ethnicities and different types of diseases
in different genetic models. In Caucasian subgroup, significant increased risks of GC geno-
type and GC+CC genotype with ADs susceptibility were found in heterozygote model (GC
vs GG, OR = 1.38, 95% CI 1.04–1.83, p = 0.024) and dominant model (GC+CC vs GG, OR
= 1.37, 95% CI 1.01–1.85, p = 0.041), respectively. Meanwhile, in other disease subgroup,
significant increased risks of C allele, CC genotype and GC+CC genotype were found in al-
lele model (C vs G, OR = 1.16, 95% CI 1.04–1.31, p = 0.010), homozygote model (CC vs
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GG, OR = 1.42, 95% CI 1.10–1.84, p = 0.006) and dominant model (GC+CC vs GG, OR =
1.25, 95% CI 1.04–1.51, p = 0.020), respectively.
Conclusions
MiR-146a rs2910164 G>C polymorphism was associated with the susceptibility of ADs.
Introduction
Autoimmune diseases (ADs) are initiated by abnormal immune response to self-antigen, and
then come the results including immune-mediated tissue destruction and chronic disabilities
[1]. There are more than 100 diseases and syndromes in ADs, which cause a heavy economic
burden in the world, about more than $100 billion annually [2]. More and more evidence indi-
cated that genetic backgrounds play an important role in the pathogenesis of ADs, which may
be controlled by a common set of susceptibility genes [3, 4].
MicroRNAs (miRNAs) are non-coding single-stranded RNA molecules. By binding to 3’
un-translated regions (UTRs) of targeted messenger RNAs, the miRNAs can repress, degrade
or silence the gene expression [5, 6]. Therefore, miRNAs have been demonstrated to affect vari-
ous functions in both innate and adaptive immune response [7, 8]. Among them, the micro-
RNA-146a (miR-146a) was reported to be involved in both innate and adaptive immunity,
especially played an important role in autoimmune disease [8, 9].
Single nucleotide polymorphisms (SNPs) or mutations in miRNAs may alter the expression
level of the gene and the susceptibility of some diseases [10–13]. Many studies on the relation-
ship between miR-146a rs2910164 G>C polymorphism and susceptibility of ADs have been
performed so far [14–34]. However, the results remain inconsistent. Moreover, two meta-anal-
yses on this issue published in 2013 and 2014 also generated opposite conclusions [35, 36].
Based on the new case-control studies [27, 28, 30–34], we conducted this updated meta-analy-
sis according the criteria PRISMA statement [37], in order to clarify the association between
miR-146a rs2910164 G>C polymorphism and susceptibility of ADs.
Materials and Methods
Publication search
A systematic search was performed in PubMed, OvidSP and Chinese National Knowledge In-
frastructure (CNKI) databases covering all papers published prior to September 8th, 2014. The
searching strategy was as follow: (autoimmune OR autoimmune disease OR autoimmunity)
AND (polymorphism OR polymorphisms OR variation OR variations OR mutation OR muta-
tions OR variant OR variants) AND (Has-mir-146a OR miR146a OR microRNA-146a OR
miR-146 OR miR-146a OR rs2910164). The references in the studies were also read to find ad-
ditional publications on the topic. Articles included should meet the criteria below: (1) case-
control study; (2) evaluation of miR-146a rs2910164 G>C polymorphism and risk of ADs; (3)
available and usable data of genotype frequency. The articles were excluded if they meet the ex-
clusion criteria below: (1) a case report, review or descriptive study; (2) a lack of normal popu-
lation as controls; (3) not show the evaluation of miR-146a rs2910164; (4) duplicate data in
the studies.
microRNA-146a Polymorphisms and Risk of Autoimmune Diseases
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Date extraction
Two authors (CL and WF) independently extracted the data from eligible studies. Different
data extracted by CL and WF were checked by the third author YZ. The remained disagree-
ments were discussed and judged by these three authors. The following information was ex-
tracted: the first author, publication year, diseases, country, ethnicity, genotyping methods,
number of cases and controls, the gender distribution of cases and controls, number of geno-
types and alleles, Hardy-Weinberg equilibrium (HWE) in control subjects, frequency of G al-
lele in controls. Ethnicities were categorized as Caucasian, East Asian, Latin-American and
Mediterranean. Study qualities were judged according to the criteria modified from previous
publications [38–40] (See S1 Table. “Scale for methodological quality assessment”).
Statistical analysis
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated as a measure of the asso-
ciation between miR-146a rs2910164 G>C polymorphism and ADs risk. The widely reported
genetic models, allele model, heterozygote model, homozygote model, dominant model and re-
cessive model, were used. In addition to comparing the pooled effects among all subjects, the
stratified comparisons were also conducted according to different ethnicities and different dis-
eases. In order to evaluate the accumulation of evidence, the cumulative meta-analysis was per-
formed. The between study heterogeneity was measured by Cochran’s (Q) and Higgins’s (I2)
tests. If the heterogeneity was considered significant (p<0.05), the random effect model was
used to estimate the pooled OR. Otherwise, the fixed effect model was conducted. Also, logistic
meta-regression analysis was carried out, if there was obvious significant heterogeneity, to ex-
plore potential sources of heterogeneity. The examined characteristics include: publication
years, countries, genotyping methods, number of alleles and genotypes, number of female and
male in cases, and the frequency of G allele in controls. The HWE was examined using Chi-
square test with significance set at p<0.05. Sensitivity analysis was performed to evaluate the
effect of each study on the combined ORs by deleting each study in each time, and to evaluate
the effect of studies with low quality or without HWE on the pooled ORs by deleting these
studies. Potential publication bias was determined by using Funnel plots and Begg’s test. An
asymmetric plot and the p value less than 0.05 was recognized as significance. All statistical
analyses were performed by Stata 12.0 software (Stata Corp., College Station, TX).
Results
Study Characteristics
There were 406 articles matching the searching strategy, and additional 5 articles [20, 23, 25,
28, 31] were included by scanning the references of original papers. After step by step of screen-
ing the titles, abstracts and full-texts of the articles, as shown in Fig 1, 21 articles were recog-
nized appropriate for this meta-analysis, including 24 studies for rs2910164, 11 studies more
than the previous meta-analysis published in 2014 [36].
Within the 21 articles, five kinds of genotyping methods were used. There were 4 racial in-
cluded, Caucasian, East Asian, Latin-American and Mediterranean. According the different
types of diseases, these studies were divided into five subgroups. The studies on Rheumatoid
Arthritis (RA), Psoriatic Arthritis (PsA), Juvenile RA (JRA) and Juvenile Idiopathic Arthritis-
Enthesitis-Related Arthritis (JIA-ERA) were included into Inflammatory Arthritis (IA) sub-
group. The studies on Ulcerative Colitis (UC) and Crohn’s Disease (CD) were included into In-
flammatory Bowel Disease (IBD) subgroup. Among these studies, the patients with Behcet’s
Disease (BD), Vogt-Koyanagi-Harada syndrome (VKH), Fuchs Uveitis Syndrome (FUS) and
microRNA-146a Polymorphisms and Risk of Autoimmune Diseases
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Pediatric Uveitis (PU) were all suffering uveitis, which was a common syndrome of ADs. So
the Uveitis subgroup was formed. The remained studies, except that for Systemic Lupus Ery-
thematosus (SLE), were included in other diseases subgroup. There were 5 studies not in HWE
in control groups (p<0.05), but the p value of HWE were not less than 0.01. And there was not
enough data in another study to generate the HWE in control. The detail characteristics are
shown in Table 1.
Association between miR-146a rs2910164 G>C polymorphism and ADs
risk
First, we investigated the overall association between rs2910164 and susceptibility of ADs. No
significant difference of the pooled OR was found in any genetic model. However, in terms of
stratified analysis, the significance emerged. In Caucasian subgroup, significant increased risks
of GC genotype and GC+CC genotype with ADs susceptibility were found in heterozygote
model (GC vs GG, OR = 1.38, 95% CI 1.04–1.83, p = 0.024) and dominant model (GC+CC vs
GG, OR = 1.37, 95% CI 1.01–1.85, p = 0.041), respectively (Table 2, Fig 2A and B).
Meanwhile, in other disease subgroup, significant increased risks of C allele, CC genotype
and GC+CC genotype with ADs were found in allele model (C vs G, OR = 1.16, 95% CI 1.04–
1.31, p = 0.010), homozygote model (CC vs GG, OR = 1.42, 95% CI 1.10–1.84, p = 0.006) and
dominant model (GC+CC vs GG, OR = 1.25, 95% CI 1.04–1.51, p = 0.020), respectively
(Table 2, Fig 2C, D, E). There was not any significance in IA, SLE, IBD and Uveitis subgroup.
Fig 1. Flowchart for identification of studies included in the meta-analysis. In 411 articles, 51 were
found not related to ADs and 43 were found not related to miR-146a by scanning the titles. After that, 233
articles were recognized as reviews, 37 were found not related to human patients and 8 articles were
repeated papers by reviewing the abstracts. The full-texts of the left 39 articles were carefully reviewed, in
which 18 articles were found not about rs2910164. At last, 21 articles were remained for this meta-analysis,
which included 24 case-control studies for rs2910164.
doi:10.1371/journal.pone.0121918.g001
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However, a trend of increased disease risk of C allele could be found in allele model (C vs G,
OR = 1.48, 95% CI 0.99–2.21, p = 0.057) in IBD subgroup (Table 2).
The cumulative meta-analysis showed that the significance of ORs emerged after the studies
published in 2013 enrolled in Caucasian subgroup (Fig 3A and B), while after the studies pub-
lished in 2014 enrolled in other disease subgroup (Fig 3C, D, and E).
Fig 3. Cumulative meta-analysis of the association between rs2910164 and ADs risk. Every rhombus
represents the pooled OR when studies accumulated over time, and the horizontal line represents the 95%
CI of the pooled ORs. (A) Heterozygote model, GC vs GG, Caucasian subgroup, randommodel. (B)
Dominant model, GC+CC vs GG, Caucasian subgroup, randommodel. (C) Allele model, C vs G, Other
diseases subgroup, fixed model. (D) Homozygote model, CC vs GG, Other diseases subgroup, fixed model.
(E)Dominant model, GC+CC vs GG, Other diseases subgroup, fixed model.
doi:10.1371/journal.pone.0121918.g003
Fig 2. Forest plots of ADs risk associated with rs2910164. (A-B) Forest plots of ADs risk associated with
rs2910164 stratified analyzed by ethnicities. (A) Heterozygote model, GC vs GG, Caucasian subgroup,
randommodel. (B) Dominant model, GC+CC vs GG, Caucasian subgroup, randommodel. (C-E) Forest plots
of ADs risk associated with rs2910164 stratified analyzed by diseases. (C) Allele model, C vs G, Other
diseases subgroup, fixed model. (D) Homozygote model, CC vs GG, Other diseases subgroup, fixed model.
(E)Dominant model, GC+CC vs GG, Other diseases subgroup, fixed model. OR: odds ratio; 95% CI: 95%
confidence interval.
doi:10.1371/journal.pone.0121918.g002
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Evaluation of heterogeneity
The heterogeneities among studies were obvious in the overall comparisons (I2 = 77.9%, Tau2 =
0.044, p = 0.000). The meta-regression analysis was conducted to further explore sources of het-
erogeneity. We assessed allele comparison by potential sources of publication year, country, gen-
otyping methods, number of genotypes and alleles, and number of female and male in cases.
None of the potential sources above could explain the heterogeneity by meta-regression analysis.
However, when we compared the frequencies of G allele in controls, we found that the heteroge-
neity could partly (Adjusted R2 = 32.7%) explained by the variation of frequencies of G allele
in controls.
Sensitivity and publication bias analysis
We performed the sensitivity analysis to test the influence of a single study on the overall meta-
analysis by deleting each study once a time. As a result, the pooled estimate didn’t show signifi-
cant difference, which indicated that the results in this meta-analyses were statistically reliable.
Moreover, the pooled ORs did not vary much even after the three studies [15, 24, 34] with low
quality or six studies [15, 16, 19, 24, 27, 34] without HWE removed (Fig 4). No evidence of
publication bias was found in current meta-analysis, identified by the Funnel plots, Egger’s test
(p = 0.261) and Begg’s test (p = 0.862) (Fig 5).
Discussion
Solid evidences had shown that miRNAs played important roles in the regulation of cell differ-
entiation, proliferation, metabolism, apoptosis and tumorigenesis [41]. MiR-146a was one of
Fig 4. Sensitivity analysis of association of rs2910164 and ADs risk. (A) Pooled analysis of association
of rs2910164 and ADs risk. Allele model, C vs G. (B) Sensitivity analysis by iteratively removing one study at
a time. (C) Sensitivity analysis by removing three studies with low quality. (D) Sensitivity analysis by removing
six studies without HWE.
doi:10.1371/journal.pone.0121918.g004
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the first miRNAs identified to be involved in innate immune response, and further demonstrat-
ed to be related to several types of cancers [42–44].
One SNP of miR-146a, rs2910164 G>C, was found not only related to cancer, but also relat-
ed to some kinds of ADs [29]. Accumulating evidences emerged to distinguish if there was any
relationship between rs2910164 and susceptibility of ADs. However, the results were inconsis-
tent. A meta-analysis published in 2013 showed that there was not any association between
rs2910164 and ADs risk [35]. While they did not include a study published by Luo et al [16] in
2011. Maybe due to there was only frequency data of allele and was not any data of each geno-
type in Luo’s study, which did not meet the inclusion criteria of this meta-analysis [35]. On the
contrary, another meta-analysis published in 2014 did find some association there [36], howev-
er, some already published studies [15, 20, 25] prior their search date at April 2013 were not in-
cluded although they should be. Moreover, the only significances of ORs were found in GG
+CC/GC genetic model [36], not in the five well used genetic models as shown in the previous
meta-analysis [35]. After that, other researchers published several new case-control studies
about this topic in 2013 and 2014 [27, 28, 30–34]. So, it was needed to do an updated meta-
analysis which included all the published manuscripts, in order to make a clarified conclusion.
In this meta-analysis, we enrolled 24 studies and pooled the corresponding data including
7591 cases and 9677 controls, and all data of these samples were available in the original publi-
cations. Our analysis revealed that there was not any significance of pooled OR. However, in
stratified analyses, we found GC genotype and GC+CC genotype were significantly related to
the increased susceptibility of ADs in Caucasian subgroup. As in other diseases subgroup, sig-
nificantly increased risk was observed to be associated with C allele, CC genotype and GC+CC
genotype in allele model, homozygote model and dominant model, respectively. All these dif-
ferences were not found in the two previous meta-analyses [35, 36]. These differences between
our data and that in previous meta-analyses may be explained by the different study number
and different sample size enrolled in these analyses. As we included more studies and an en-
larged sample size, our data should be recognized more powerful.
In cumulative meta-analysis, we found the significance of ORs after new case-control stud-
ies published in 2013 and 2014 enrolled. These data demonstrated the correlation of rs2910164
and susceptibility of ADs. In addition, not only sensitivity analysis by iteratively removing one
study at a time, but also analysis removing three studies [15, 24, 34] with low quality or six
Fig 5. Publication bias on the rs2910164 polymorphism and ADs risk.
doi:10.1371/journal.pone.0121918.g005
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studies [15, 16, 19, 24, 27, 34] without HWE, showed similar and consistent results. Thus, the
results of cumulative meta-analysis and sensitivity analysis indicated the robustness of our
data. There were still some limitations in our studies. First, although there were 24 studies in-
cluded, the studies for some stratified analyses were limited. For example, there were only two
studies for Latin-American subgroup. Second, there were obvious heterogeneities between dif-
ferent groups for some genetic model. Although the meta-regression and sensitivity analyses
were conducted and we found that the variation of G allele frequency in controls could partly
explain some heterogeneity, the results still needed to be treated with caution. Third, although
there was some significance of ORs in some genetic models, the summary ORs were not very
high even after the new studies enrolled in the cumulate meta-analyses. So, future well-de-
signed large studies on this topic will be welcomed to confirm this conclusion. Finally, only
rs2910164 in miR-146a was included in this study. However, there were more other SNPs in
miR-146a and more other genes could also contribute to susceptibility of ADs. Not only the ef-
fect of the SNPs or genes, but also the interaction or network among these genetic locations,
should be studied in the future. Furthermore, our data did not study the gene-environment in-
teractions based on the lack of this interaction from the original case-control studies. So, in the
future, studies investigating the gene-environment interactions would also help to make clear
of the role of the genetic locations in the pathogen of ADs.
Conclusions
Taken together, our data demonstrated that the miR-146a rs2910164 G>C polymorphism was
related to the susceptibility of ADs and our findings should be validated by future well-de-
signed large studies.
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